文献速递心外重症与机械循环支持瓣膜外科

功能性二尖瓣反流与房颤对左心室辅助装置患者的预后影响

Consequences of functional mitral regurgitation and atrial fibrillation in patients with left ventricular assist devices.
PubMed 文献 · J Heart Lung Transplant · 2020-09-03

该单中心回顾性研究纳入2010至2017年380例LVAD植入患者,按持续性/永久性房颤(PeAF)与显著功能性二尖瓣反流(FMR)分组。2年总死亡率15%,合并PeAF与显著FMR组2年生存率仅47%,且为独立死亡预测因子(HR 4.31)。

要点

  • LVAD患者中PeAF合并显著FMR者2年生存率仅47%,预后差。
  • 该组合是死亡的独立预测因子(HR 4.31,95%CI 2.19-8.46)。
  • 单纯PeAF或单纯显著FMR者2年生存率分别为87%和89%。

核心结论

  • 显著FMR与PeAF共存可能是LVAD植入患者的不良预后标志。

研究设计与样本

  • 显著FMR定义为二尖瓣反流彩色射流面积与左心房面积比值>20%。
  • PeAF定义为LVAD植入时持续性或永久性房颤。

主要发现

  • 2年内共56例(15%)死亡。
  • 2年生存率:无PeAF无显著FMR组81%,无PeAF有显著FMR组89%,有PeAF无显著FMR组87%,有PeAF有显著FMR组47%,同期MVS无PeAF组87%,同期MVS有PeAF组79%(log-rank p<0.001)。
  • 多变量Cox模型显示有PeAF有显著FMR组为死亡的独立预测因子(HR 4.31,95%CI 2.19-8.46,p<0.001)。

临床怎么用

  • 对LVAD候选患者应评估FMR与房颤共存状态以识别高危人群。
  • 合并显著FMR与PeAF者预后差,需加强围术期与长期管理。

局限性

  • 单中心回顾性设计,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Functional mitral regurgitation (MR) (FMR) and atrial fibrillation (AF) are common in patients undergoing left ventricular assist device (LVAD) implantation. However, the impact of FMR and AF on clinical outcomes is uncertain. This study aimed to investigate the characteristics and prognostic significance of FMR and AF in patients with LVADs. METHODS: We retrospectively reviewed all patients who underwent LVAD implantation at our center between January 2010 and December 2017. We defined significant FMR as the ratio of MR color jet area to left atrial area of >20% and persistent or permanent AF (PeAF) as persistent or permanent AF at LVAD implantation. RESULTS: A total of 380 patients were included in this analysis. Patients were divided into 6 groups: patients with no PeAF and no significant FMR (Group 1), patients with no PeAF but with significant FMR (Group 2), patients with PeAF but no significant FMR (Group 3), patients with PeAF and significant FMR (Group 4), patients with concomitant mitral valve surgery (MVS) at LVAD implantation and without PeAF (Group 5), and patients with concomitant MVS and with PeAF (Group 6). A total of 56 patients (15%) died within 2 years. Kaplan-Meier curve analysis demonstrated a 2-year survival of 81% in Group 1, 89% in Group 2, 87% in Group 3, 47% in Group 4, 87% in Group 5, and 79 % in Group 6 (log-rank test, p < 0.001). The multivariable Cox proportional-hazards model showed that classification in Group 4 was an independent predictor of mortality (hazard ratio, 4.31; 95% CI: 2.19-8.46; p < 0.001). CONCLUSIONS: The coexistence of significant FMR and PeAF may represent a poor prognostic marker in patients undergoing LVAD implantation.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Hayashi H, Naka Y, Sanchez J, et al. Consequences of functional mitral regurgitation and atrial fibrillation in patients with left ventricular assist devices. J Heart Lung Transplant. 2020. PMID: 32994093. doi:10.1016/j.healun.2020.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。